SAGES Magazine

Fire Put out the of inflammation References: 1. Mezavant® approved Professional Information, August 2013. 2. Tenjarla S, RomasantaV, Zeijdner E,Villa R, Moro L. Release of 5-aminosalicylate from an MMX mesalamine tablet during transit through a simulated gastrointestinal tract system. AdvTher . 2007; 24 (4):826-40. 3. Brunner M, AssandriR,KletterK,TschurlovitM,CorradM,VillaR, etal .Gastrointestinal transitand5-ASA release fromanewmesalazineextended-release formulation. AlimentPharmacolTher .2003; 17 :395–402. 4. TenjarlaS,AbinusawaA. In-vitro characterizationof5-aminosalicylicacid release fromMMXmesalamine tabletsanddeterminationof tabletcoating thickness. AdvTher. 2011; 28 (1):62–72. 5. RubinDT,AnanthakrishnanAN,SiegelCA,SauerBG,LongMD.ACGClinicalGuideline:UlcerativeColitis inAdults. Am JGastroenterol. 2019; 114 (3):384-413. 6. KammMA,SandbronWJ,GassullM,SchreiberS, JackowskiL, ButlerT, etal. Once-daily,high-concentrationMMXmesalamine inactiveulcerativecolitis. Gastroenterology. 2007; 132 :66–75. 7. KammMA,LichtensteinGR,SandbornWJ,SchreiberS,LeesK,BarrettK, etal. Randomised trialofonce-or twice-dailyMMXmesalazine formaintenanceof remission inulcerative colitis. Gut. 2008; 57 :893–902. Mezavant® (entericcoated,prolonged release tablet.)Each tabletcontainsmesalazine1200mg.Reg.No.45/11/0463. For fullprescribing information, refer to theMEZAVANT®Professional InformationasapprovedbySAHPRA.Takeda (Pty)Ltd,Reg.No.:1982/011215/07, BuildingA,MonteCircle,64MontecasinoBoulevard,Fourways2191.Tel:+27115143000.MarketedanddistributedbyAdcock IngramLimited.Reg.No.:1949/034385/06.PrivateBagX69,Bryanston,2021,SouthAfrica.CustomerCare:0860ADCOCK/232625.www.adcock.com C-APROM/ZA/MEZ/0013 Mezavant® is a valuable option in the management of patients with mild to moderate ulcerative colitis 3 Delivers 5-ASA throughout the colon 1-4 • Multi-matrix system technology (MMX)® provides prolonged drug release 1-4 Delivers treatment targets 5 • Patients achieved clinical and endoscopic remission at week 8 6 • Over 64 % of patients maintained clinical and endoscopic remission at 12 months 7 Once daily oral treatment for induction and maintenance 1